Stocks and Investing Stocks and Investing
Fri, January 31, 2020

Matthew Harrison Maintained (VRTX) at Buy with Increased Target to $251 on, Jan 31st, 2020


Published on 2024-10-26 21:11:14 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy with Increased Target from $250 to $251 on, Jan 31st, 2020.

Matthew has made no other calls on VRTX in the last 4 months.



There are 4 other peers that have a rating on VRTX. Out of the 4 peers that are also analyzing VRTX, 0 agree with Matthew's Rating of Hold.



These are the ratings of the 4 analyists that currently disagree with Matthew


  • Hartaj Singh of "Oppenheimer" Maintained at Buy with Increased Target to $265 on, Wednesday, January 8th, 2020
  • Edward Tenthoff of "Piper Sandler" Maintained at Buy with Increased Target to $284 on, Monday, January 6th, 2020
  • Alethia Young of "Cantor Fitzgerald" Maintained at Buy with Increased Target to $229 on, Tuesday, November 19th, 2019
  • Robyn Karnauskas of "Citigroup" Maintained at Strong Buy with Increased Target to $225 on, Tuesday, October 22nd, 2019

Contributing Sources